Are Apremilast tablets a biologic drug?

Apremilast is an oral small molecule drug that is a phosphodiesterase 4 (PDE4) inhibitor. Its mechanism regulates the production of inflammatory factors by selectively inhibiting the PDE4 enzyme, thereby playing a therapeutic role in autoimmune diseases. Unlike typical biological agents, apremilast does not target specific immune molecules through proteins or antibodies, but interferes with signaling pathways through small molecules. Therefore, in terms of pharmacological classification, it does not belong to the category of biological agents. Biological agents are usually protein drugs produced by living cells, such as monoclonal antibodies or fusion proteins, which are often used to treat rheumatoid arthritis, psoriasis, Crohn's disease, etc., while apremilast is a chemically synthesized small molecule targeted drug.

The therapeutic effect of apremilast is mainly reflected in immune regulation. It can reduce the expression of pro-inflammatory cytokines such asTNF-α, IL-17 and IL-23, while increasing the production of the anti-inflammatory factor IL-10, thereby improving the inflammatory response. This mechanism allows apremilast to show good efficacy in the treatment of plaque psoriasis and psoriatic arthritis, especially in moderate to severe patients, especially those who do not respond well to traditional non-biological agents or topical treatments. Compared with biologics, oral administration of apremilast offers greater convenience and reduces injection-related discomfort and potential infection risks.

In addition, from a drug safety perspective, the side effects spectrum of apremilast mainly includes mild to moderate gastrointestinal reactions, headaches, and weight changes, without showing the risk of immunosuppression or injection site reactions associated with typical biological agents. For this reason, apremilast provides patients with a convenient and safe immunomodulation option, while forming a complementary treatment strategy with biological agents, which is particularly important when patients have limited tolerance to biological agents or have injection barriers.

Reference materials:https://go.drugbank.com/drugs/DB05676